SIX3-AS1: A Potential Drug Target and Biomarker (G100506108)

Target Name: SIX3-AS1

NCBI ID: G100506108

SIX3-AS1

Other Name(s): SIX3 antisense RNA 1 | SIX3-AS1 variant 1 | SIX3-AS1 variant 2 | SIX3OS

SIX3-AS1: A Potential Drug Target and Biomarker

Six3-AS1, also known as SIX3-AS1-CTR, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its unique structure and expression pattern have made it an attractive target for researchers to study, and recent studies have suggested that it may also have potential as a biomarker for certain diseases.

The protein Six3-AS1 is composed of 114 amino acids and has a molecular weight of 13.9 kDa. It is expressed in a variety of tissues, including the brain, heart, and kidneys, and has been shown to localize to the endoplasmic reticulum (ER) and the nuclear envelope (NE) in these tissues. Its expression pattern suggests that it is involved in the regulation of various cellular processes, including cell signaling, protein synthesis, and intracellular signaling pathways.

One of the key features of Six3-AS1 is its ability to interact with various signaling molecules, including Shc/FAK, a protein that is involved in cell signaling and has been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The interaction between Six3-AS1 and Shc/FAK suggests that Six3-AS1 may be a useful biomarker for these diseases, as changes in its expression levels or function may indicate the presence of these conditions.

Another potential mechanism by which Six3-AS1 may be involved in disease is its role in the regulation of inflammation. Inflammation is a complex process that is involved in the immune response and has been implicated in a variety of diseases, including heart disease, neurodegenerative disorders, and cancer. Six3-AS1 has been shown to be involved in the regulation of inflammation in various tissues, including the brain and the kidneys. Its expression has been shown to be increased in response to pro-inflammatory stimuli, and its function in these processes has been suggested as a potential target for the development of therapeutic interventions for inflammation-related diseases.

In addition to its potential role in cell signaling and inflammation, Six3-AS1 has also been shown to be involved in the regulation of cell survival and metabolism. Its expression has been shown to be associated with various cellular processes, including cell survival, apoptosis, and autophagy. These processes are important for maintaining the health and function of cells, and changes in their regulation have been implicated in a variety of diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.

Given its unique structure and expression pattern, as well as its involvement in various cellular processes, Six3-AS1 has potential as a drug target or biomarker for a variety of diseases. Its expression has been shown to be involved in the regulation of various signaling pathways, including cell signaling, protein synthesis, intracellular signaling pathways, inflammation, and cell survival and metabolism. Further research is needed to fully understand its role in these processes and its potential as a drug target or biomarker.

Protein Name: SIX3 Antisense RNA 1

The "SIX3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SIX3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets